technetium Tc 99m ethylenediamine-tetramethylenephosphonic acid

Also Known As:

99mTc-EDTMP

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

1.	Spondylarthropathies 04/01/2003 - "The most significant difference was observed for 99mTc-EDTMP, which shows a high retention in kidney, reaching ca. 2% ID after 90min p.i.v.Although preliminary clinical evaluations suggest that 99mTc-EDTMP possesses limited value for bone scintigraphy, application of the radiopharmaceutical for specific diagnostic purposes may still be considered, e.g., investigation of bone metastases or ossification processes in inflammatory spondyloarthropathy."
2.	Neoplasm Metastasis (Metastasis) 04/01/2003 - "The most significant difference was observed for 99mTc-EDTMP, which shows a high retention in kidney, reaching ca. 2% ID after 90min p.i.v.Although preliminary clinical evaluations suggest that 99mTc-EDTMP possesses limited value for bone scintigraphy, application of the radiopharmaceutical for specific diagnostic purposes may still be considered, e.g., investigation of bone metastases or ossification processes in inflammatory spondyloarthropathy."
3.	Myocardial Infarction 06/01/1976 - "Double-labeling of experimental acute myocardial infarcts with 113mIn- and 99mTc-EDTMP." 06/01/1976 - "The feasibility of double-labeling of acute myocardial infarcts with 113mIn-EDTMP [ethylenediaminetetra(methylene phosphonic acid)] and 99mTc-EDTMP was evaluated. "